Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare Biotechnology
Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger)
Bullboard Posts
User Avatar Image
(3)
•••
Comment by themagicboxon Apr 30, 2020 4:01pm
110 Views
Post# 30973154

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:New Update from Dan L Himself.

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:New Update from Dan L Himself.LOL! Johnnysins is a bonafide retard. The no halt. And SP keeps dipping. And yea, you are a joke on CEO. 


JohnnySins wrote: Thanks Pez for the link. The info/email is 10 days old...which is when other emails from Christina were circulating indicating the delays as well. You should really preface your comments indicating "this 10 day old info"... it would give more substance to your argument. Basically, you have no clue what's going on, or at least no more than the rest of us. :) And we are all waiting patiently for results, with the hope they come very soon, but definitely sooner than later. 

No need to try and play it up like it is brand new info when it isn't. Now I know why you aren't going to post any emails from Dan... either a) they don't exist, or b) they are 10 days old and hold the same weight as the link you attached. ;) Nice try for the shorts kid. 


Bullboard Posts
Dealroom for high-potential pre-IPO opportunities